No Data
No Data
UroGen Pharma Announces Encouraging Results From a Phase 1 Dose-Escalation Study Evaluating...
UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% From the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Guggenheim Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40
UroGen Pharma Is Maintained at Neutral by Goldman Sachs
This H.B. Fuller Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Scotiabank Initiates UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $23